Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/OSMR_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/OSMR_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/OSMR_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/OSMR_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/OSMR_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/OSMR_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00321035 | Cervix | CC | positive regulation of response to external stimulus | 95/2311 | 427/18723 | 5.44e-09 | 5.03e-07 | 95 |
GO:00313494 | Cervix | CC | positive regulation of defense response | 60/2311 | 278/18723 | 9.38e-06 | 2.11e-04 | 60 |
GO:00507273 | Cervix | CC | regulation of inflammatory response | 75/2311 | 386/18723 | 3.95e-05 | 6.18e-04 | 75 |
GO:00507294 | Cervix | CC | positive regulation of inflammatory response | 34/2311 | 142/18723 | 9.51e-05 | 1.25e-03 | 34 |
GO:00192213 | Cervix | CC | cytokine-mediated signaling pathway | 84/2311 | 472/18723 | 3.25e-04 | 3.44e-03 | 84 |
GO:0002526 | Liver | NAFLD | acute inflammatory response | 26/1882 | 112/18723 | 3.68e-05 | 9.23e-04 | 26 |
GO:00025262 | Liver | HCC | acute inflammatory response | 62/7958 | 112/18723 | 4.06e-03 | 1.77e-02 | 62 |
GO:00321037 | Oral cavity | OSCC | positive regulation of response to external stimulus | 203/7305 | 427/18723 | 1.79e-04 | 1.22e-03 | 203 |
GO:00192214 | Oral cavity | OSCC | cytokine-mediated signaling pathway | 222/7305 | 472/18723 | 2.02e-04 | 1.35e-03 | 222 |
GO:00313495 | Oral cavity | OSCC | positive regulation of defense response | 127/7305 | 278/18723 | 1.32e-02 | 4.39e-02 | 127 |
GO:001922112 | Oral cavity | EOLP | cytokine-mediated signaling pathway | 94/2218 | 472/18723 | 2.36e-07 | 7.37e-06 | 94 |
GO:003210314 | Oral cavity | EOLP | positive regulation of response to external stimulus | 84/2218 | 427/18723 | 1.72e-06 | 3.99e-05 | 84 |
GO:003134912 | Oral cavity | EOLP | positive regulation of defense response | 53/2218 | 278/18723 | 3.00e-04 | 2.81e-03 | 53 |
GO:00507274 | Oral cavity | EOLP | regulation of inflammatory response | 66/2218 | 386/18723 | 1.34e-03 | 9.33e-03 | 66 |
GO:001922122 | Oral cavity | NEOLP | cytokine-mediated signaling pathway | 88/2005 | 472/18723 | 1.37e-07 | 4.80e-06 | 88 |
GO:003210323 | Oral cavity | NEOLP | positive regulation of response to external stimulus | 81/2005 | 427/18723 | 2.04e-07 | 6.74e-06 | 81 |
GO:003134922 | Oral cavity | NEOLP | positive regulation of defense response | 47/2005 | 278/18723 | 1.05e-03 | 7.99e-03 | 47 |
GO:00025265 | Oral cavity | NEOLP | acute inflammatory response | 23/2005 | 112/18723 | 1.59e-03 | 1.11e-02 | 23 |
GO:005072712 | Oral cavity | NEOLP | regulation of inflammatory response | 60/2005 | 386/18723 | 1.99e-03 | 1.33e-02 | 60 |
GO:00507295 | Oral cavity | NEOLP | positive regulation of inflammatory response | 25/2005 | 142/18723 | 8.58e-03 | 4.15e-02 | 25 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa0415114 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa041516 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
hsa0415113 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
hsa0415123 | Oral cavity | EOLP | PI3K-Akt signaling pathway | 73/1218 | 354/8465 | 7.03e-04 | 2.69e-03 | 1.59e-03 | 73 |
hsa04630 | Oral cavity | EOLP | JAK-STAT signaling pathway | 35/1218 | 166/8465 | 1.15e-02 | 3.07e-02 | 1.81e-02 | 35 |
hsa0415133 | Oral cavity | EOLP | PI3K-Akt signaling pathway | 73/1218 | 354/8465 | 7.03e-04 | 2.69e-03 | 1.59e-03 | 73 |
hsa046301 | Oral cavity | EOLP | JAK-STAT signaling pathway | 35/1218 | 166/8465 | 1.15e-02 | 3.07e-02 | 1.81e-02 | 35 |
hsa0415141 | Oral cavity | NEOLP | PI3K-Akt signaling pathway | 79/1112 | 354/8465 | 8.42e-07 | 9.92e-06 | 6.24e-06 | 79 |
hsa0415151 | Oral cavity | NEOLP | PI3K-Akt signaling pathway | 79/1112 | 354/8465 | 8.42e-07 | 9.92e-06 | 6.24e-06 | 79 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
OSMR | SNV | Missense_Mutation | novel | c.855N>T | p.Lys285Asn | p.K285N | Q99650 | protein_coding | deleterious(0.05) | possibly_damaging(0.601) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
OSMR | SNV | Missense_Mutation | novel | c.1403A>G | p.Tyr468Cys | p.Y468C | Q99650 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
OSMR | SNV | Missense_Mutation | novel | c.1859C>T | p.Ser620Phe | p.S620F | Q99650 | protein_coding | tolerated(0.58) | benign(0.165) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
OSMR | SNV | Missense_Mutation | rs370407842 | c.2186N>T | p.Thr729Met | p.T729M | Q99650 | protein_coding | tolerated(0.2) | possibly_damaging(0.572) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
OSMR | SNV | Missense_Mutation | novel | c.1484N>G | p.Leu495Arg | p.L495R | Q99650 | protein_coding | deleterious(0) | possibly_damaging(0.556) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
OSMR | SNV | Missense_Mutation | rs371267287 | c.782C>T | p.Thr261Met | p.T261M | Q99650 | protein_coding | tolerated(0.11) | benign(0.068) | TCGA-E6-A2P9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
OSMR | SNV | Missense_Mutation | novel | c.1049N>C | p.Ile350Thr | p.I350T | Q99650 | protein_coding | tolerated(1) | benign(0) | TCGA-EO-A22S-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
OSMR | SNV | Missense_Mutation | | c.1392N>T | p.Lys464Asn | p.K464N | Q99650 | protein_coding | deleterious(0.04) | possibly_damaging(0.617) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
OSMR | SNV | Missense_Mutation | | c.2535N>T | p.Lys845Asn | p.K845N | Q99650 | protein_coding | tolerated(0.19) | benign(0.003) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
OSMR | SNV | Missense_Mutation | novel | c.1817N>T | p.Thr606Ile | p.T606I | Q99650 | protein_coding | tolerated(0.24) | benign(0.265) | TCGA-JU-AAVI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |